|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giovannucci E and Michaud D: The role of
obesity and related metabolic disturbances in cancers of the colon,
prostate, and pancreas. Gastroenterology. 132:2208–2225. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gunter MJ and Leitzmann MF: Obesity and
colorectal cancer: Epidemiology, mechanisms and candidate genes. J
Nutr Biochem. 17:145–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cade WT: Diabetes-related microvascular
and macrovascular diseases in the physical therapy setting. Phys
Ther. 88:1322–1335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Yee D: Diabetes and cancer: A consensus report. Diabetes Care.
33:1674–1685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kasuga M, Ueki K, Tajima N, Noda M, Ohashi
K, Noto H, Goto A, Ogawa W, Sakai R, Tsugane S, et al: Report of
the Japan diabetes Society/Japanese cancer association joint
committee on diabetes and cancer. Cancer Sci. 104:965–976. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishino K, Mutoh M, Totsuka Y and Nakagama
H: Metabolic syndrome: A novel high-risk state for colorectal
cancer. Cancer Lett. 334:56–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pais R, Silaghi H, Silaghi AC, Rusu ML and
Dumitrascu DL: Metabolic syndrome and risk of subsequent colorectal
cancer. World J Gastroenterol. 15:5141–5148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimizu M, Kubota M, Tanaka T and Moriwaki
H: Nutraceutical approach for preventing obesity-related colorectal
and liver carcinogenesis. Int J Mol Sci. 13:579–595. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu
F, Rabidou K, Fang R, Tan L, Xu S, et al: Glucose-regulated
phosphorylation of TET2 by AMPK reveals a pathway linking diabetes
to cancer. Nature. 559:637–641. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hata K, Kubota M, Shimizu M, Moriwaki H,
Kuno T, Tanaka T, Hara A and Hirose Y: Monosodium glutamate-induced
diabetic mice are susceptible to azoxymethane-induced colon
tumorigenesis. Carcinogenesis. 33:702–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tuominen I, Al-Rabadi L, Stavrakis D,
Karagiannides I, Pothoulakis C and Bugni JM: Diet-induced obesity
promotes colon tumor development in azoxymethane-treated mice. PLoS
One. 8:e609392013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fukuta K, Shirakami Y, Maruta A, Obara K,
Iritani S, Nakamura N, Kochi T, Kubota M, Sakai H, Tanaka T and
Shimizu M: Preventive effects of pentoxifylline on the development
of colonic premalignant lesions in obese and diabetic mice. Int J
Mol Sci. 18(pii): E4132017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kubota M, Shimizu M, Sakai H, Yasuda Y,
Terakura D, Baba A, Ohno T, Tsurumi H, Tanaka T and Moriwaki H:
Preventive effects of curcumin on the development of
azoxymethane-induced colonic preneoplastic lesions in male
C57BL/KsJ-db/db obese mice. Nutr Cancer. 64:72–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shimizu M, Shirakami Y, Sakai H, Adachi S,
Hata K, Hirose Y, Tsurumi H, Tanaka T and Moriwaki H:
(−)-Epigallocatechin gallate suppresses azoxymethane-induced
colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer
Prev Res (Phila). 1:298–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang YT, Tsai HL, Kung YT, Yeh YS, Huang
CW, Ma CJ, Chiu HC and Wang JY: Dose-dependent relationship between
metformin and colorectal cancer occurrence among patients with type
2 Diabetes-A nationwide cohort study. Transl Oncol. 11:535–541.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horibe Y, Adachi S, Ohno T, Goto N, Okuno
M, Iwama M, Yamauchi O, Kojima T, Saito K, Ibuka T, et al:
Alpha-glucosidase inhibitor use is associated with decreased
colorectal neoplasia risk in patients with type 2 diabetes mellitus
receiving colonoscopy: A retrospective study. Oncotarget.
8:97862–97870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Imamura M, Nakanishi K, Suzuki T, Ikegai
K, Shiraki R, Ogiyama T, Murakami T, Kurosaki E, Noda A, Kobayashi
Y, et al: Discovery of ipragliflozin (ASP1941): A novel C-glucoside
with benzothiophene structure as a potent and selective sodium
glucose co-transporter 2 (SGLT2) inhibitor for the treatment of
type 2 diabetes mellitus. Bioorg Med Chem. 20:3263–3279. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tahrani AA, Barnett AH and Bailey CJ: SGLT
inhibitors in management of diabetes. Lancet Diabetes Endocrinol.
1:140–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fonseca VA, Ferrannini E, Wilding JP,
Wilpshaar W, Dhanjal P, Ball G and Klasen S: Active- and
placebo-controlled dose-finding study to assess the efficacy,
safety, and tolerability of multiple doses of ipragliflozin in
patients with type 2 diabetes mellitus. J Diabetes Complications.
27:268–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tahara A, Kurosaki E, Yokono M, Yamajuku
D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H,
et al: Effects of sodium-glucose cotransporter 2 selective
inhibitor ipragliflozin on hyperglycaemia, oxidative stress,
inflammation and liver injury in streptozotocin-induced type 1
diabetic rats. J Pharm Pharmacol. 66:975–987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tahara A, Kurosaki E, Yokono M, Yamajuku
D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H,
et al: Pharmacological profile of ipragliflozin (ASP1941), a novel
selective SGLT2 inhibitor, in vitro and in vivo. Naunyn
Schmiedebergs Arch Pharmacol. 385:423–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaji K, Nishimura N, Seki K, Sato S,
Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya
K, et al: Sodium glucose cotransporter 2 inhibitor canagliflozin
attenuates liver cancer cell growth and angiogenic activity by
inhibiting glucose uptake. Int J Cancer. 142:1712–1722. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Obara K, Shirakami Y, Maruta A, Ideta T,
Miyazaki T, Kochi T, Sakai H, Tanaka T, Seishima M and Shimizu M:
Preventive effects of the sodium glucose cotransporter 2 inhibitor
tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in
obese and diabetic mice. Oncotarget. 8:58353–58363. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scafoglio C, Hirayama BA, Kepe V, Liu J,
Ghezzi C, Satyamurthy N, Moatamed NA, Huang J, Koepsell H, Barrio
JR and Wright EM: Functional expression of sodium-glucose
transporters in cancer. Proc Natl Acad Sci USA. 112:E4111–E4119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Utsunomiya K, Shimmoto N, Senda M,
Kurihara Y, Gunji R, Kameda H, Tamura M, Mihara H and Kaku K:
Japanese study of tofogliflozin with type 2 diabetes mellitus
patients in an observational study of the elderly (J-STEP/EL): A
12-week interim analysis. J Diabetes Investig. 7:755–763. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Terakura D, Shimizu M, Iwasa J, Baba A,
Kochi T, Ohno T, Kubota M, Shirakami Y, Shiraki M, Takai K, et al:
Preventive effects of branched-chain amino acid supplementation on
the spontaneous development of hepatic preneoplastic lesions in
C57BL/KsJ-db/db obese mice. Carcinogenesis. 33:2499–2506. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hata K, Tanaka T, Kohno H, Suzuki R, Qiang
SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A and Mori H:
Beta-catenin-accumulated crypts in the colonic mucosa of juvenile
ApcMin/+ mice. Cancer Lett. 239:123–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyazaki T, Shirakami Y, Kubota M, Ideta
T, Kochi T, Sakai H, Tanaka T, Moriwaki H and Shimizu M: Sodium
alginate prevents progression of non-alcoholic steatohepatitis and
liver carcinogenesis in obese and diabetic mice. Oncotarget.
7:10448–10458. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shirakami Y, Shimizu M, Kubota M, Ohno T,
Kochi T, Nakamura N, Sumi T, Tanaka T, Moriwaki H and Seishima M:
Pentoxifylline prevents nonalcoholic steatohepatitis-related liver
pre-neoplasms by inhibiting hepatic inflammation and lipogenesis.
Eur J Cancer Prev. 25:206–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shirakami Y, Gottesman ME and Blaner WS:
Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in
lecithin:retinol acyltransferase-deficient mice primarily through
retinoid actions immediately after carcinogen administration.
Carcinogenesis. 33:268–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nagata T, Fukuzawa T, Takeda M, Fukazawa
M, Mori T, Nihei T, Honda K, Suzuki Y and Kawabe Y: Tofogliflozin,
a novel sodium-glucose co-transporter 2 inhibitor, improves renal
and pancreatic function in db/db mice. Br J Pharmacol. 170:519–531.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bird RP and Good CK: The significance of
aberrant crypt foci in understanding the pathogenesis of colon
cancer. Toxicol Lett. 112-113:395–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamada Y and Mori H: Pre-cancerous lesions
for colorectal cancers in rodents: A new concept. Carcinogenesis.
24:1015–1019. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kubota M, Shimizu M, Sakai H, Yasuda Y,
Ohno T, Kochi T, Tsurumi H, Tanaka T and Moriwaki H:
Renin-angiotensin system inhibitors suppress azoxymethane-induced
colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.
Biochem Biophys Res Commun. 410:108–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Szlosarek P, Charles KA and Balkwill FR:
Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer.
42:745–750. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen J, Wu A, Sun H, Drakas R, Garofalo C,
Cascio S, Surmacz E and Baserga R: Functional significance of type
1 insulin-like growth factor-mediated nuclear translocation of the
insulin receptor substrate-1 and beta-catenin. J Biol Chem.
280:29912–29920. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Itzkowitz SH and Yio X: Inflammation and
cancer IV. Colorectal cancer in inflammatory bowel disease: The
role of inflammation. Am J Physiol Gastrointest Liver Physiol.
287:G7–G17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weisberg SP, McCann D, Desai M, Rosenbaum
M, Leibel RL and Ferrante AW Jr: Obesity is associated with
macrophage accumulation in adipose tissue. J Clin Invest.
112:1796–1808. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu H, Barnes GT, Yang Q, Tan G, Yang D,
Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA and Chen H:
Chronic inflammation in fat plays a crucial role in the development
of obesity-related insulin resistance. J Clin Invest.
112:1821–1830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
De Bruijn KM, Arends LR, Hansen BE,
Leeflang S, Ruiter R and van Eijck CH: Systematic review and
meta-analysis of the association between diabetes mellitus and
incidence and mortality in breast and colorectal cancer. Br J Surg.
100:1421–1429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gonzalez N, Prieto I, Del Puerto-Nevado L,
Portal-Nuñez S, Ardura JA, Corton M, Fernández-Fernández B,
Aguilera O, Gomez-Guerrero C, Mas S, et al: 2017 update on the
relationship between diabetes and colorectal cancer: Epidemiology,
potential molecular mechanisms and therapeutic implications.
Oncotarget. 8:18456–18485. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu L, Nagata N, Nagashimada M, Zhuge F, Ni
Y, Chen G, Mayoux E, Kaneko S and Ota T: SGLT2 inhibition by
empagliflozin promotes fat utilization and browning and attenuates
inflammation and insulin resistance by polarizing M2 macrophages in
Diet-induced obese mice. EBioMedicine. 20:137–149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ealey KN, Xuan W, Lu S and Archer MC:
Colon carcinogenesis in liver-specific IGF-I-deficient (LID) mice.
Int J Cancer. 122:472–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Giovannucci E, Pollak MN, Platz EA,
Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE and
Hankinson SE: A prospective study of plasma insulin-like growth
factor-1 and binding protein-3 and risk of colorectal neoplasia in
women. Cancer Epidemiol Biomarkers Prev. 9:345–349. 2000.PubMed/NCBI
|
|
47
|
Olivo-Marston SE, Hursting SD, Lavigne J,
Perkins SN, Maarouf RS, Yakar S and Harris CC: Genetic reduction of
circulating insulin-like growth factor-1 inhibits
azoxymethane-induced colon tumorigenesis in mice. Mol Carcinog.
48:1071–1076. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kaku K, Watada H, Iwamoto Y, Utsunomiya K,
Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, et al:
Efficacy and safety of monotherapy with the novel sodium/glucose
cotransporter-2 inhibitor tofogliflozin in Japanese patients with
type 2 diabetes mellitus: A combined Phase 2 and 3 randomized,
placebo-controlled, double-blind, parallel-group comparative study.
Cardiovasc Diabetol. 13:652014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Suzuki M, Honda K, Fukazawa M, Ozawa K,
Hagita H, Kawai T, Takeda M, Yata T, Kawai M, Fukuzawa T, et al:
Tofogliflozin, a potent and highly specific sodium/glucose
cotransporter 2 inhibitor, improves glycemic control in diabetic
rats and mice. J Pharmacol Exp Ther. 341:692–701. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chao EC and Henry RR: SGLT2 inhibition-a
novel strategy for diabetes treatment. Nat Rev Drug Discov.
9:551–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hanabata Y, Nakajima Y, Morita K, Kayamori
K and Omura K: Coexpression of SGLT1 and EGFR is associated with
tumor differentiation in oral squamous cell carcinoma. Odontology.
100:156–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lai B, Xiao Y, Pu H, Cao Q, Jing H and Liu
X: Overexpression of SGLT1 is correlated with tumor development and
poor prognosis of ovarian carcinoma. Arch Gynecol Obstet.
285:1455–1461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu H, Ertay A, Peng P, Li J, Liu D, Xiong
H, Zou Y, Qiu H, Hancock D, Yuan X, et al: SGLT1 is required for
the survival of triple-negative breast cancer cells via
potentiation of EGFR activity. Mol Oncol. 13:1874–1886. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Madunić IV, Madunić J, Breljak D, Karaica
D and Sabolić I: Sodium-glucose cotransporters: New targets of
cancer therapy? Arh Hig Rada Toksikol. 69:278–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ren J, Bollu LR, Su F, Gao G, Xu L, Huang
WC, Hung MC and Weihua Z: EGFR-SGLT1 interaction does not respond
to EGFR modulators, but inhibition of SGLT1 sensitizes prostate
cancer cells to EGFR tyrosine kinase inhibitors. Prostate.
73:1453–1461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rosenwasser RF, Rosenwasser JN, Sutton D,
Choksi R and Epstein B: Tofogliflozin: A highly selective SGLT2
inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc).
50:739–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
